Advanced

Which patient groups should be asked to participate in first-in-human trials of stem-cell-based therapies?

Hug, Kristina LU and Hermerén, Göran LU (2012) In Journal of Clinical Ethics 23(3). p.256-271
Abstract
The aims of this article are to consider (1) whether there are medical and societal differences among diseases regarding which patient groups should be asked to participate in first-in-human (FIH) trials of stem-cell-based therapies; (2) any differences in the light of values generally endorsed by different types of ethical theories, since the question in the title of this article is value laden, and its answer depends on which values one wants to promote and protect, and how they are ranked in importance; (3) whether the answer to that question is disease-specific, or whether it depends on factors common to several diseases. To illustrate these problems, we use Parkinson's disease (PD) and Huntington's disease (HD), between which there... (More)
The aims of this article are to consider (1) whether there are medical and societal differences among diseases regarding which patient groups should be asked to participate in first-in-human (FIH) trials of stem-cell-based therapies; (2) any differences in the light of values generally endorsed by different types of ethical theories, since the question in the title of this article is value laden, and its answer depends on which values one wants to promote and protect, and how they are ranked in importance; (3) whether the answer to that question is disease-specific, or whether it depends on factors common to several diseases. To illustrate these problems, we use Parkinson's disease (PD) and Huntington's disease (HD), between which there are important medical and societal differences. Moreover, research on stem-cell-based therapies for these diseases is being translated from research to practice. This approach to the problem can be applied to decision making about similar problems raised by other diseases that exhibit the same types of differences. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Ethics
volume
23
issue
3
pages
256 - 271
publisher
Journal of Clinical Ethics
external identifiers
  • pmid:23256407
  • scopus:84872044683
ISSN
1046-7890
language
English
LU publication?
yes
id
7aaf70f4-1523-432c-8eca-a4ab25d3e93f (old id 3347031)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23256407?dopt=Abstract
date added to LUP
2013-01-02 17:08:28
date last changed
2017-01-01 07:49:28
@article{7aaf70f4-1523-432c-8eca-a4ab25d3e93f,
  abstract     = {The aims of this article are to consider (1) whether there are medical and societal differences among diseases regarding which patient groups should be asked to participate in first-in-human (FIH) trials of stem-cell-based therapies; (2) any differences in the light of values generally endorsed by different types of ethical theories, since the question in the title of this article is value laden, and its answer depends on which values one wants to promote and protect, and how they are ranked in importance; (3) whether the answer to that question is disease-specific, or whether it depends on factors common to several diseases. To illustrate these problems, we use Parkinson's disease (PD) and Huntington's disease (HD), between which there are important medical and societal differences. Moreover, research on stem-cell-based therapies for these diseases is being translated from research to practice. This approach to the problem can be applied to decision making about similar problems raised by other diseases that exhibit the same types of differences.},
  author       = {Hug, Kristina and Hermerén, Göran},
  issn         = {1046-7890},
  language     = {eng},
  number       = {3},
  pages        = {256--271},
  publisher    = {Journal of Clinical Ethics},
  series       = {Journal of Clinical Ethics},
  title        = {Which patient groups should be asked to participate in first-in-human trials of stem-cell-based therapies?},
  volume       = {23},
  year         = {2012},
}